FDA set to open comments on AI use in pharma manufacturing
The FDA wants to know what people think about the use of AI in the pharma manufacturing space.
According to a public inspection document, the FDA plans to publish a request for information notice on Wednesday, aiming to gather public comments on “emerging and advanced” manufacturing tech, specifically in artificial intelligence’s use in pharma manufacturing.
The paper will lay out “areas for considerations and policy development” from the Center for Drug Evaluation and Research (CDER) surrounding AI in pharmaceutical manufacturing. The paper is meant to encourage and gather feedback from the public, people in the industry, as well as CDER and the Center for Biologics Evaluation and Research (CBER).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.